by April Breyer Menon | Oct 30, 2017
Watch Ha Kung Wong, Amanda Forys, and Molly Burich discuss the question, “Will biosimilar manufacturers seeking interchangeability have an effect on how reference product sponsors attempt to protect market share?” as part of the The Center for Biosimilars™...
by April Breyer Menon | Oct 23, 2017
As of July 20, 2017, there have been at least 363 IPR petitions filed against patents that were listed in the FDA Orange Book, and 74 IPR petitions filed against patents that have been identified as reading on FDA Purple Book (CDER) listed biologic drugs. Of these 437...
by April Breyer Menon | Oct 5, 2017
Download PDF Download PDF Click on the “Subscribe” link above for future BiologicsHQ Monthly Injections delivered to your inbox.
by April Breyer Menon | Sep 1, 2017
April Breyer Menon, Corinne Atton and Ha Kung Wong reveal that PTAB decisions have been consistent but drug patents challenged multiple times are more likely to be found unpatentable. There has been some concern regarding the statistics periodically issued by the...
by April Breyer Menon | Jun 12, 2017
Download PDF Download PDF Corinne Atton has experience litigating cases concerning a wide range of pharmaceuticals and biotechnology, including DNA sequences, DNA sequencing technologies, recombinant...
by April Breyer Menon | Jun 12, 2017
In a June 12, 2017 decision authored by Justice Clarence Thomas, the United States Supreme Court in Sandoz v. Amgen ruled that, under the Biologics Price Competition and Innovation Act (BPCIA), biosimilar makers can give notice of commercial marketing before the...